Blood-Based DNA Methylation Biomarkers to Identify Risk and Progression of Cardiovascular Disease.

Non-communicable diseases (NCDs) are the leading cause of death worldwide, with cardiovascular disease (CVD) accounting for half of all NCD-related deaths. The biological onset of CVD may occur long before the development of clinical symptoms, hence the urgent need to understand the molecular alterations underpinning CVD, which would facilitate intervention strategies to prevent or delay the onset of the disease. There is evidence to suggest that CVD develops through a complex interplay between genetic, lifestyle, and environmental factors.

Improving genetic variant identification for quantitative traits using ensemble learning-based approaches.

Background: Genome-wide association studies (GWAS) are rapidly advancing due to the improved resolution and completeness provided by Telomere-to-Telomere (T2T) and pangenome assemblies. While recent advancements in GWAS methods have primarily focused on identifying genetic variants associated with discrete phenotypes, approaches for quantitative traits (QTs) remain underdeveloped. This has often led to significant variants being overlooked due to biases from genotype multicollinearity and strict p-value thresholds.

Drug-drug interaction study with itraconazole supplemented with physiologically based pharmacokinetic modelling to characterize the effect of CYP3A inhibitors on venglustat pharmacokinetics.

Aims: Venglustat is an oral glucosylceramide synthase inhibitor under clinical investigation to treat various lysosomal storage diseases. Metabolism is a main pathway for its elimination in humans with CYP3A being the major contributor. This study aims to evaluate effect of CYP3A inhibition (using itraconazole) on venglustat exposure and to develop and validate a physiologically based pharmacokinetic (PBPK) model to assess effects of additional CYP3A inhibitors of varying potencies on venglustat pharmacokinetics.

Adjuvant Chemotherapy in Colon Cancer: Simple is Better… Less is More.

A significant number of patients with colorectal cancer (CRC) benefit from adjuvant therapy. While 6 months of FOLFOX is standard of care, newer regimens like CAPOX and SOX allow for shorter durations. Trials of importance include SCOT (U.

Early postnatal weight loss and its association with outcomes in very preterm neonates: a systematic review and meta-analysis.

Introduction: Ideal early postnatal weight loss (PWL) and its association with mortality and morbidity in preterm infants is not well known. This review explored the association between early PWL and outcomes in very premature infants (<32 weeks).

Methods: This is a systematic review and meta-analyses of the observational studies.